Stockreport

Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025 [Yahoo! Finance]

Merck & Company, Inc. (new)  (MRK) 
Last merck & company, inc. (new) earnings: 4/28 06:45 am Check Earnings Report
US:NYSE Investor Relations: investors.merck.com/home/default.aspx
PDF Advancements in other clinical programs and Research and Innovation (R&I) activity to deliver news flow and fuel growth in Transgene's portfolio over the next 24 months [Read more]